121 related articles for article (PubMed ID: 35777027)
41. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
42. Intergrated analysis of ELMO1, serves as a link between tumour mutation burden and epithelial-mesenchymal transition in hepatocellular carcinoma.
Peng H; Zhang Y; Zhou Z; Guo Y; Huang X; Westover KD; Zhang Z; Chen B; Hua Y; Li S; Xu R; Lin N; Peng B; Shen S
EBioMedicine; 2019 Aug; 46():105-118. PubMed ID: 31324602
[TBL] [Abstract][Full Text] [Related]
43. High expression of PARD3 predicts poor prognosis in hepatocellular carcinoma.
Li S; Huang J; Yang F; Zeng H; Tong Y; Li K
Sci Rep; 2021 May; 11(1):11078. PubMed ID: 34040099
[TBL] [Abstract][Full Text] [Related]
44. Clinical Value of lncRNA LUCAT1 Expression in Liver Cancer and its Potential Pathways.
Jiao Y; Li Y; Ji B; Cai H; Liu Y
J Gastrointestin Liver Dis; 2019 Dec; 28(4):439-447. PubMed ID: 31826070
[TBL] [Abstract][Full Text] [Related]
45. Prognostic role of tumor mutation burden in hepatocellular carcinoma after radical hepatectomy.
Cai H; Zhang Y; Zhang H; Cui C; Li C; Lu S
J Surg Oncol; 2020 May; 121(6):1007-1014. PubMed ID: 31995247
[TBL] [Abstract][Full Text] [Related]
46. Screening and clinical significance of lymph node metastasis-related genes within esophagogastric junction adenocarcinoma.
Han R; Chen G; Li M; Peng ZM; Xu L
Cancer Med; 2021 Aug; 10(15):5088-5100. PubMed ID: 34152098
[TBL] [Abstract][Full Text] [Related]
47. TP53 and LRP1B Co-Wild Predicts Improved Survival for Patients with LUSC Receiving Anti-PD-L1 Immunotherapy.
Yu J; Fan Z; Zhou Z; Zhang P; Bai J; Li X; Tang M; Fan N; Wu X; Nie X; Chen X; Ma D; Chen X; Cui L; Xia X; Yang L; Yi X; Li L
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884443
[TBL] [Abstract][Full Text] [Related]
48. Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies.
Voutsadakis IA
Curr Oncol; 2022 Feb; 29(3):1390-1407. PubMed ID: 35323317
[No Abstract] [Full Text] [Related]
49. Upregulation of Stress-Induced Protein Kinase CK1 Delta is associated with a Poor Prognosis for patients with Hepatocellular Carcinoma.
Zhang H; Qiu C; Zeng H; Zhu W; Lyu W; Lao X
Genet Test Mol Biomarkers; 2021 Jul; 25(7):504-514. PubMed ID: 34280005
[No Abstract] [Full Text] [Related]
50. Identification of Potential Biomarkers From Hepatocellular Carcinoma With MT1 Deletion.
Zhang R; Huang M; Wang H; Wu S; Yao J; Ge Y; Lu Y; Hu Q
Pathol Oncol Res; 2021; 27():597527. PubMed ID: 34257549
[No Abstract] [Full Text] [Related]
51. MARCKS on Tumor-Associated Macrophages is Correlated with Immune Infiltrates and Poor Prognosis in Hepatocellular Carcinoma.
Ren X; Ju Y; Wang C; Wei R; Sun H; Zhang Q
Cancer Invest; 2021 Oct; 39(9):756-768. PubMed ID: 34279157
[TBL] [Abstract][Full Text] [Related]
52. The Prognostic Significance of
Li Z; Cui Y; Duan Q; Zhang J; Shao D; Cao X; Gao Y; Wang S; Li J; Jones OD; Lei X; Wang L; Zhou X; Xu M; Ma J; Liu Y; Xu X
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361587
[TBL] [Abstract][Full Text] [Related]
53. Protein Regulator of Cytokinesis 1 (PRC1) Upregulation Promotes Immune Suppression in Liver Hepatocellular Carcinoma.
Zhang C; Xu H; Sui X; Wu T; Chen B; Wang S; Wang X
J Immunol Res; 2022; 2022():7073472. PubMed ID: 35983074
[TBL] [Abstract][Full Text] [Related]
54. A scoring model based on ferroptosis genes for prognosis and immunotherapy response prediction and tumor microenvironment evaluation in liver hepatocellular carcinoma.
Gao L; Xue J; Liu X; Cao L; Wang R; Lei L
Aging (Albany NY); 2021 Nov; 13(22):24866-24881. PubMed ID: 34839280
[TBL] [Abstract][Full Text] [Related]
55. Identification of Diagnostic Biomarkers and Subtypes of Liver Hepatocellular Carcinoma by Multi-Omics Data Analysis.
Ouyang X; Fan Q; Ling G; Shi Y; Hu F
Genes (Basel); 2020 Sep; 11(9):. PubMed ID: 32899915
[TBL] [Abstract][Full Text] [Related]
56. Study of the G Protein Nucleolar 2 Value in Liver Hepatocellular Carcinoma Treatment and Prognosis.
Dong Y; Cai Q; Fu L; Liu H; Ma M; Wu X
Biomed Res Int; 2021; 2021():4873678. PubMed ID: 34337013
[TBL] [Abstract][Full Text] [Related]
57. Potential Diagnostic and Prognostic Values of CBX8 Expression in Liver Hepatocellular Carcinoma, Kidney Renal Clear Cell Carcinoma, and Ovarian Cancer: A Study Based on TCGA Data Mining.
Lin J; Chen L; Wu D; Lin J; Liu B; Guo C
Comput Math Methods Med; 2022; 2022():1372879. PubMed ID: 35813444
[TBL] [Abstract][Full Text] [Related]
58. Multi-omics data identified TP53 and LRP1B as key regulatory gene related to immune phenotypes via EPCAM in HCC.
Shi L; Cao J; Lei X; Shi Y; Wu L
Cancer Med; 2022 May; 11(10):2145-2158. PubMed ID: 35150083
[TBL] [Abstract][Full Text] [Related]
59. Prognostic model of patients with liver cancer based on tumor stem cell content and immune process.
Kong W; Gao M; Jin Y; Huang W; Huang Z; Xie Z
Aging (Albany NY); 2020 Aug; 12(16):16555-16578. PubMed ID: 32852285
[TBL] [Abstract][Full Text] [Related]
60. Comprehensive analysis of tumour mutation burden and the immune microenvironment in hepatocellular carcinoma.
Xie F; Bai Y; Yang X; Long J; Mao J; Lin J; Wang D; Song Y; Xun Z; Huang H; Yang X; Zhang L; Mao Y; Sang X; Zhao H
Int Immunopharmacol; 2020 Dec; 89(Pt A):107135. PubMed ID: 33189609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
